Tonix Pharmaceuticals Files 8-K

Ticker: TNXP · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1430306

Sentiment: neutral

Topics: corporate-filing, financial-reporting

Related Tickers: TNXP

TL;DR

TONX filed an 8-K on 8/18/25 with updated corporate info.

AI Summary

Tonix Pharmaceuticals Holding Corp. filed an 8-K on August 18, 2025, reporting on other events and financial statements. The filing details the company's principal executive offices located at 26 Main Street, Chatham, New Jersey, 07928, and its telephone number as (862) 799-8599. The company was incorporated in Nevada and its fiscal year ends on December 31.

Why It Matters

This 8-K filing provides updated corporate information and financial reporting details for Tonix Pharmaceuticals, which is crucial for investors to track the company's operational status and compliance.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Tonix Pharmaceuticals Holding Corp.?

The filing serves as a Current Report, indicating the date of the earliest event reported as August 18, 2025, and includes information on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

Where are Tonix Pharmaceuticals Holding Corp.'s principal executive offices located?

The principal executive offices are located at 26 Main Street, Suite 101, Chatham, New Jersey 07928.

What is the telephone number for Tonix Pharmaceuticals Holding Corp.?

The registrant's telephone number, including area code, is (862) 799-8599.

In which state was Tonix Pharmaceuticals Holding Corp. incorporated?

The company was incorporated in Nevada.

What is the fiscal year end for Tonix Pharmaceuticals Holding Corp.?

The company's fiscal year ends on December 31.

Filing Stats: 854 words · 3 min read · ~3 pages · Grade level 12.4 · Accepted 2025-08-18 07:01:21

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On August 18, 2025, at 8:30 a.m. Tonix Pharmaceuticals Holding Corp. (the "Company") will hold a webcast and conference call to discuss the U.S. Food and Drug Administration's ("FDA") approval of Tonmya TM (cyclobenzaprine HCl sublingual tablets), which was investigated as TNX-102 SL, for the treatment of fibromyalgia in adults. In connection with the webcast and conference call, the Company will be reviewing a presentation, a copy of which is furnished hereto as Exhibit 99.01, and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01

Item 8.01 Other Events. On August 18, 2025, at 8:30 a.m. the Company will hold a webcast and conference call to discuss the FDA's approval of Tonmya. In connection with the webcast and conference call to review the FDA's approval of Tonmya, the Company will be reviewing the presentation attached hereto as Exhibit 99.1, which is incorporated herein by reference. Forward- Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product launch, commercialization and development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibit No. Description 99.01 US Approval of Tonmya for the Treatment of Fibromyalgia 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TONIX PHARMACEUTICALS HOLDING CORP. Date: August 18, 2025 By: /s/ Bradley Saenger Bradley Saenger Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing